Published OnlineFirst August 31, 2012; DOI: 10.1158/0008-5472.CAN-12-2026 

Therapeutics, Targets, and Chemical Biology

Cancer
Research

GF-15, a Novel Inhibitor of Centrosomal Clustering,
Suppresses Tumor Cell Growth In Vitro and In Vivo

Marc S. Raab1,4,6, Iris Breitkreutz3,6, Simon Anderhub2, Mads H. R√∏nnest8,9, Blanka Leber2,
Thomas O. Larsen9, Ludmila Weiz2,4, Gleb Konotop4, Patrick J. Hayden6, Klaus Podar3,6,
Johannes Fruehauf7, Felix Nissen5, Walter Mier5, Uwe Haberkorn5, Anthony D. Ho1,
Hartmut Goldschmidt1,3, Kenneth C. Anderson6, Mads H. Clausen8, and Alwin Kr‚Ç¨amer1,2

Abstract

In contrast to normal cells, malignant cells are frequently aneuploid and contain multiple centrosomes. To allow
for bipolar mitotic division, supernumerary centrosomes are clustered into two functional spindle poles in many
cancer cells. Recently, we have shown that griseofulvin forces tumor cells with supernumerary centrosomes to
undergo multipolar mitoses resulting in apoptotic cell death. Here, we describe the characterization of the novel
small molecule GF-15, a derivative of griseofulvin, as a potent inhibitor of centrosomal clustering in malignant cells.
At concentrations where GF-15 had no signiÔ¨Åcant impact on tubulin polymerization, spindle tension was markedly
reduced in mitotic cells upon exposure to GF-15. Moreover, isogenic cells with conditional centrosome ampliÔ¨Åcation
were more sensitive to GF-15 than parental controls. In a wide array of tumor cell lines, mean inhibitory
concentrations (IC50) for proliferation and survival were in the range of 1 to 5 mmol/L and were associated with
apoptotic cell death. Importantly, treatment of mouse xenograft models of human colon cancer and multiple
myeloma resulted in tumor growth inhibition and signiÔ¨Åcantly prolonged survival. These results show the in vitro
and in vivo antitumor efÔ¨Åcacy of a prototype small molecule inhibitor of centrosomal clustering and strongly support
the further evaluation of this new class of molecules. Cancer Res; 72(20); 5374‚Äì85. √ì2012 AACR.

Introduction

Centrosomes are small cytoplasmic organelles, which con-
sist of a pair of centrioles embedded in pericentriolar material
and act as microtubule-organizing centers. During mitosis,
centrosomes function as spindle poles, directing the formation
of bipolar spindles, a process essential for accurate chromo-
somal segregation (1, 2). Centrosomes duplicate precisely once
per cell cycle to assure spindle bipolarity, with each daughter

Authors' AfÔ¨Åliations: 1Department of Internal Medicine V, 2Clinical Coop-
eration Unit Molecular Hematology/Oncology, German Cancer Research
Center and Department of Internal Medicine V; 3National Center for Tumor
Diseases, University of Heidelberg; 4Max-Eder Group Experimental Ther-
apies for Hematologic Malignancies, German Cancer Research Center
(DKFZ); 5Department of Nuclear Medicine, University Hospital Heidelberg,
Heidelberg, Germany; 6Department of Medical Oncology, Dana-Farber
Cancer Institute; 7Beth Israel Deaconess Medical Center, Harvard Medical
School, Boston, Massachusetts; 8Center for Nanomedicine and Thera-
nostics & Department of Chemistry; and 9Center for Microbial Biotechnol-
ogy, Department of Systems Biology, Technical University of Denmark,
Kgs. Lyngby, Denmark

Note: Supplementary data for this article are available at Cancer Research
Online (http://cancerres.aacrjournals.org/).

M.S. Raab and I. Breitkreutz contributed equally to this work.
Corresponding Author: Alwin Kr‚Ç¨amer, Clinical Cooperation Unit Molec-
ular Hematology/Oncology, German Cancer Research Center and Depart-
ment of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld
581, 69120 Heidelberg, Germany. Phone: 49-6221-42-1440; Fax: 49-
6221-42-1444; E-mail: a.kraemer@dkfz.de

doi: 10.1158/0008-5472.CAN-12-2026
√ì2012 American Association for Cancer Research.

cell receiving one centrosome upon cytokinesis. Centrosome
ampliÔ¨Åcation is frequent in both solid tumors and hematologic
malignancies, and is linked to tumorigenesis and aneuploidy
(3‚Äì10). The extent of centrosomal aberrations correlates with
the degree of chromosomal instability and malignant behavior
in tumor cell lines, mouse tumor models, and human tumors
(6, 9‚Äì12).

In mitosis, supernumerary centrosomes can lead to the
formation of multipolar spindles, which is a hallmark of many
tumor types (8). Multipolar cell division, however, is antago-
nistic to cell viability (13, 14). Most progeny derived from a
multipolar mitosis will undergo apoptosis. To circumvent this
problem, many cancer cells seem to have mechanisms that
suppress multipolar division, the best studied being clustering
of supernumerary centrosomes into 2 spindle poles enabling
bipolar division (8, 13‚Äì20). Bipolar spindle formation via
centrosomal clustering is associated with an increased fre-
quency of lagging chromosomes during anaphase, thereby
explaining the link between supernumerary centrosomes and
chromosomal instability (14, 15).

The mechanisms of centrosomal clustering in tumor cells
are incompletely understood. Recent genome-wide RNAi
screens in cells containing supernumerary centrosomes sug-
gest the involvement of the spindle assembly checkpoint and
spindle tension as controlled by the cortical actin cytoskeleton,
cell adhesion molecules as well as centrosome and kinetochore
components in this process (19, 20).

Supernumerary centrosomes are almost exclusively found
in a wide variety of neoplastic disorders but rarely in

5374

Cancer Res; 72(20) October 15, 2012

Downloaded from 

cancerres.aacrjournals.org 

on July 23, 2015. ¬© 2012 American Association for Cancer Research. 

Published OnlineFirst August 31, 2012; DOI: 10.1158/0008-5472.CAN-12-2026 

nontransformed cells. Therefore, inhibition of centrosomal
clustering with consequential induction of multipolar spindles
and subsequent cell death would speciÔ¨Åcally target tumor cells
with no effect on normal cells with regular centrosome content
(8, 17). Using a phenotype-based screening strategy, we have
recently found that griseofulvin induces spindle multipolarity,
mitotic arrest, and subsequent cell death in multiple tumor cell
lines but not in diploid Ô¨Åbroblasts and keratinocytes with
normal centrosome content (13). Chemical optimization of
griseofulvin led to the development of compounds with sig-
niÔ¨Åcantly increased activity and mean inhibitory concentra-
tions (IC50) of proliferation and survival in the lower micro-
molar range when applied to the human squamous cell car-
cinoma cell line SCC114, which had been used for the initial
screening (21).

Here, we present evidence that the exposure of tumor cells to
the griseofulvin derivative GF-15 leads to reduced spindle
tension, spindle multipolarity, and the inhibition of centroso-
mal clustering, culminating in the induction of apoptosis in
vitro and in vivo.

Materials and Methods
Materials

0
-methylcyclohex-2

0R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-
(2S,6
0
0
0
1
-benzyloxy-
-benzyloxy-6
-(2
0
2
-demethoxygriseofulvin; GF-15) was synthesized following
the procedures described recently (21). Caspase-8, caspase-9,
g-tubulin, BubR1, and PARP antibodies were purchased from
Santa Cruz Biotechnology. The centrin antibody was kindly
provided by J. Salisbury (Rochester).

0
-one) (2

0
-en-4

Cell culture

All human multiple myeloma (MM) cell lines (RPMI-8226,
OPM-2, NCI-H929, OPM-1, KMS-12BM, KMS-12PE, KMS-11,
KMS-18, U-266, MM1.S, LR5, Dox40, MM1.R) and primary
patient MM cells were cultured in RPMI 1640 medium sup-
plemented with 10% heat-inactivated FBS (Harlan), 100 U/mL
penicillin, 10 mg/mL streptomycin, and 2 mmol/L L-glutamine
(Cellgro). Leukemia lines used were HEL, MOLM14, and Ku812
and cultured as described above. Solid tumor cell lines com-
prised HeLa (cervical carcinoma), HT29, HCT116, SW480
(colorectal carcinoma), PANC1, PACA1 (pancreatic carcino-
ma), and LN229 (glioblastoma). HS4, KM105, KM104 (bone
marrow stromal cells, BMSC), THLE3 (liver cells), peripheral
blood mononuclear cells (PBMC), and primary BMSCs served
as nonmalignant controls. All solid tumor cell
lines and
nonmalignant controls were grown in Dulbecco's ModiÔ¨Åed
Eagle's Medium supplemented with 10% heat-inactivated FBS
(Harlan), 100 U/mL penicillin, 10 mg/mL streptomycin, and 2
mmol/L L-glutamine (Cellgro). All cell
lines are regularly
authenticated by Ô¨Ångerprinting before backup freezing and
are kept less than 4 months in culture.

Isolation of patient tumor cells

Patients provided informed consent in accordance with the
Declaration of Helsinki. Following approval by the Institutional
Review Board of the University of Heidelberg, MM patient cells
(96% CD38

) were obtained as described (22).

CD45RA

√æ

 

Centrosomal Cluster Inhibition

Cell lysis and immunoblotting

Cell lysis and Western blot analysis were conducted as

described previously (22).

Evaluation of cell viability

Cell viability was examined using the MTT (Sigma Chemical)
colorimetric assay, as previously described (23). BrieÔ¨Çy, cells
were plated in 96-well microtitre plates at a density of 2‚Äì3 104
cells per well, and each plate was incubated for 24 and/or 48
hours, with MTT added to each well for at least 4 hours. The
absorbance of each well was measured at 570/630 nm using a
spectrophotometer (Molecular Devices). Each condition was
analyzed in at least 3 replicates, and the results are presented as
the mean  SD of replicates of a representative experiment
that was repeated at least 3 times.

DNA synthesis and cell proliferation assay

Cell proliferation was assessed by measuring [3H]-thymidine

uptake, as described in prior studies (22).

Measurement of caspase-3/7 activation

Caspase-3/7 activation was analyzed using the Apoptosis
Detection Kit from Promega according to the recommenda-
tions of the manufacturer.

Flow cytometry

Cell-cycle analysis by Ô¨Çow cytometry was conducted as

previously described (13).

ImmunoÔ¨Çuorescence

ImmunoÔ¨Çuorescence staining was conducted as described
(24). The following Ô¨Çuorochrome-conjugated secondary anti-
bodies were used: anti-rabbit Alexa 488 (Molecular Probes) and
anti-mouse Cy3 (Jackson ImmunoResearch Laboratories).
Immunostained cells were examined using a Zeiss Axiovert
200 M Ô¨Çuorescence microscope. Images were processed with
Photoshop software (Adobe).

Tubulin polymerization assay

The effect of GF-15 on tubulin polymerization was assessed
using the tubulin polymerization assay kit (Cytoskeleton)
according to the manufacturer's recommendation.

Xenograft mouse models
To determine the in vivo activity of GF-15, beige-nude Xid
mice were inoculated s.c. in the right Ô¨Çank with 3  106 OPM2
or HT29 cells in 100 mL RPMI 1640 medium, together with 100
mL matrigel (Becton Dickinson Biosciences). When a tumor
was measurable, mice were assigned to a GF-15 treatment
group or the control group. GF-15 was dissolved in 100%
dimethyl sulfoxide (DMSO) and given daily 5 times a week by
intraperitoneal injection for indicated periods. The control
group received the carrier alone at the same schedule and route
of administration. Tumor burden was measured every
alternate day using a calliper [calculated volume ¬º 4p/3 
(width/2)2  (length/2)]. Animals were sacriÔ¨Åced when their
tumors reached 2 cm in diameter, became exulcerated, or when
the mice were moribund. Survival was evaluated from the Ô¨Årst

www.aacrjournals.org

Cancer Res; 72(20) October 15, 2012

5375

Downloaded from 

cancerres.aacrjournals.org 

on July 23, 2015. ¬© 2012 American Association for Cancer Research. 

Published OnlineFirst August 31, 2012; DOI: 10.1158/0008-5472.CAN-12-2026 

O

O O

O

O

1

Cl

O

Griseofulvin
EC50 = 25 ¬µmol/L

Sensitive resistant

C

O

O

O

O

O

Cl

O

GF-15

EC50 = 0.9 ¬µmol/L

Raab et al.

A

B

)

%

 

(
s
e
m
o
s
o
r
t
n
e
c
y
r
a
r
e
m
u
n
r
e
p
u
S

40

30

20

10

0

**

Bipolar

Declustered

Aberrant

0.375

0.75

1.5 ¬µmol/L

Centrin

DAPI            Merge

0
Œ≥

-tubulin

D‚Äô‚Äô‚Äô

D‚Äô‚Äô‚Äô‚Äô

)

%

(
 
s
l
l
e
c
 
c
i
t
o
t
i

M

100

80

60

40

20

0

r
a
l
u
g
e
R

t
n
a
r
r
e
b
a

d
e
i
f
i
l

p
m
A

d
e
r
e
t
s
u
c
e
d

l

F

Œ±

-Tubulin

BubR1                 DAPI                   Merge

O
S
M
D

l

o
x
a
T

5
1
-
F
G

5
1
-
F
G

D

Œ≥

-tubulin

Centrin

DAPI            Merge

D‚Äô

D‚Äô‚Äô

Interkinetochore distance

Tx

Mean (¬µm) SD (¬µm)

P

r DMSO

l

GF15

DMSO

GF15

a
o
p
B

i

l

r
a
o
p
i
t
l
u
M

1.70

1.52

1.54

1.35

0.32

0.32

0.34

0.32

<0.01

<0.01

l

r
a
u
g
e
R

r
a
l
o
p
b

i

d
e
i
f
i
l

p
m
A

d
e
r
e
t
s
u
c

l

E

O
S
M
D

5
1
-
F
G

G

s
t
i
n
u
e
c
n
e
c
s
e
r
u
o
l
f
 
e
v
i
t
a
e
R

l

180
160
140
120
100
80
60
40
20
0

GF

Control
25 ¬µmol/L
50 ¬µmol/L
75 ¬µmol/L
100 ¬µmol/L

X
*

s
t
i
n
u
e
c
n
e
c
s
e
r
u
o
l
f
 
e
v
i
t
a
e
R

l

160

140

120

100

80

60

40

20
0

GF-15

Control
1.0 ¬µmol/L
5.0 ¬µmol/L
12.5 ¬µmol/L
25.0 ¬µmol/L
50.0 ¬µmol/L

X
*

0

7

14

21

28 min

0

7

14

21

28

min

5376

Cancer Res; 72(20) October 15, 2012

Cancer Research

Downloaded from 

cancerres.aacrjournals.org 

on July 23, 2015. ¬© 2012 American Association for Cancer Research. 

Published OnlineFirst August 31, 2012; DOI: 10.1158/0008-5472.CAN-12-2026 

day of treatment until death. All animal studies were approved
by the Dana-Farber Animal Care and Use Committee.

0

0

0

0

-ene-4

-(4-iodo-benzyloxy)-6

Preparation of the radiolabeled GF-15 analogue

0 R)-(7-Chloro-4,6-dimethoxy-benzofuran-
[125I/131I]-(2S,6
0
3-one)-2-spiro-1
-methyl-cyclohex-
-(2
0
2
-one) was prepared by thallation-iodination with
0R)-(7-chloro-
125I-iodide or 131I-iodide (Perkin Elmer) of (2S,6
0
4,6-dimethoxy-benzofuran-3-one)-2-spiro-1
-(4-
-methyl-2
-(6
0
trimethylsilylbenzyloxy)-cyclohex-2
-one), which was in
turn synthesized from p-trimethylsilylbenzyl alcohol
(25)
using a known method (21). The radiolabeled analogue was
0R)-(7-chloro-4,6-dimethoxy-
compared with a sample of (2S,6
0
0
0
benzofuran-3-one)-2-spiro-1
-methyl-
-(4-iodobenzyloxy)-6
-(2
-one) prepared from p-iodobenzyl alcohol
cyclohex-2
(22) and found to be identical by high-performance liquid
chromatography-mass spectrometry (HPLC-MS) analysis.

-ene-4

-ene-4

0

0

0

0

Scintigraphic in vivo imaging

For imaging studies, 200 mL of a solution of the 125I-labeled
GF-15 analogue (5 MBq/mouse) was injected into the tail vein
of 6-week-old female NMRI mice. Scintigraphic images were
taken using a gamma camera (Biospace). The accumulation of
the radioactive tracer was monitored by static planar images at
5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6
hours, and 24 hours after injection.

Biodistribution studies

131I-labeled GF-15 analogue (1 MBq/mouse) was injected via
the tail vein of 6-week-old female NMRI mice. At the time
points speciÔ¨Åed, the animals were sacriÔ¨Åced, weighed, and
dissected. Organs or tissues were blotted dry and weighed. The
radioactivity was measured in a g-counter along with a sample
of the injection solution to calculate the percentage of injected
dose per gram of tissue (% ID/g).

Stability experiments

The serum stability was determined by incubation of the
125I-labeled GF-15 analogue in human serum at 37
C. Aliquots
were taken at several points in time, and the degradation was
stopped by precipitation of the serum proteins with acetoni-
trile. After incubation for 30 minutes at 0
C and a further
centrifugation step the clear supernatant was analyzed by





Centrosomal Cluster Inhibition

reverse-phase HPLC on a Chromolith Performance RP-18e
100  4.6 mm column using water and acetonitrile containing
0.1% triÔ¨Çuoroacetic acid as the eluent.

Isobologram analysis

For combination studies, data from MTT assays were con-
verted into values representing the fraction of growth affected
(FA) in drug-treated versus untreated cells and analyzed using
CalcuSyn software program (Biosoft) based on the Chou-
Talalay method. A combination index (CI) smaller than 0.9
indicates synergism, whereas 0.9 to 1.1 indicates additive and
more than 1.1 antagonistic effects.

Statistical analysis

The statistical signiÔ¨Åcance of differences observed in GF-15-
treated versus control cell cultures and mice was determined
using an unpaired Student t test or a 1-way ANOVA with
Dunnett's Multiple Comparison Test for interkinetochore dis-
tances. Overall survival in animal studies was measured using
the Kaplan‚ÄìMeier method (

, P > 0.001).

, P > 0.01;





0

Results
GF-15 leads to multipolar mitosis induction in the upper
nanomolar range

0

0

Recently, we have shown that 2

-modiÔ¨Åed derivatives of
griseofulvin are more potent inducers of multipolar mitosis
when compared with griseofulvin itself (21). Initial testing for
the ability to inhibit centrosomal clustering was conducted in
SCC114 cells, an oral squamous cell carcinoma line showing
pronounced centrosome ampliÔ¨Åcation (13, 18). GF-15 (2
-ben-
zyloxy-2
-demethoxygriseofulvin) is signiÔ¨Åcantly more potent
with regard to the induction of spindle multipolarity than
griseofulvin (Fig. 1A). The EC50 value of GF-15 for multipolar
spindle induction was 900 nmol/L, corresponding to a 27-fold
increase in activity compared with griseofulvin. Importantly,
SCC114 cells that became resistant to GF-15 after long-term
culture with increasing doses (0.2‚Äì1 mmol/L) of the compound
over a period of 10 weeks, showed signiÔ¨Åcantly less centrosome
ampliÔ¨Åcation and formed fewer multipolar spindles upon
treatment with therapeutic doses (5 mmol/L) of the drug (Fig.
1B, Supplementary Fig. S1).

To test for the contribution of centrosome declustering to
total multipolar mitosis induction after treatment with GF-

Figure 1. GF-15 is a potent and speciÔ¨Åc inducer of spindle multipolarity. A, chemical structures of griseofulvin and GF-15. SCC114 cells stably expressing
a-tubulin were treated with increasing concentrations of griseofulvin or GF-15 for 24 hours. EC50 of spindle multipolarity was assessed by
immunoÔ¨Çuorescence microscopy. B, SCC114 cells resistant to GF-15 after long-term culture with increasing concentrations of GF-15 display signiÔ¨Åcantly
fewer cells with supernumerary centrosomes than wild-type SCC114. Centrosomes were counted in interphase cells by g-tubulin/centrin coimmunostaining.
, P < 0.001. C, in PC-3 prostate cancer cells, GF-15 induces centrosomal declustering (Declustered) in cells with ampliÔ¨Åed centrosomes and spindle
multipolarity by other means (aberrant) in cells with regular centrosome content in a concentration-dependent manner. The dashed line depicts the overall
percentage of PC-3 cells with centrosome ampliÔ¨Åcation. D, spindle phenotypes of PC-3 cells upon treatment with vehicle only (D', D'') or GF-15 (D''', D'''')
according to their regular versus ampliÔ¨Åed centriole content. Cells were treated with GF-15 or vehicle only for 24 hours, spindle poles were counted by g-tubulin
staining, centrioles by centrin staining. Insets show enlargements of centrin signals at each spindle pole. All scale bars represent 5 mm. E, GF-15 reduces
spindle tension in PC-3 cells exposed to GF-15 (1 mmol/L; 24 hours). Interkinetochore distances from multipolar and bipolar spindles (table) are given
as mean and SD. Cells were stained for CREST (green), HEC1 (red), g-tubulin (purple), and DNA (40, 6-diamidino-2-phenylindole, DAPI; blue; right). Sister
kinetochores were identiÔ¨Åed by spatial correlation of HEC1 and CREST as a marker of the interkinetochore space. Distances between corresponding HEC1
signals were measured. F, GF-15 triggers the spindle assembly checkpoint. PC-3 cells were exposed to DMSO control, taxol (10 nmol/L) as a positive control,
and GF-15 (0.75 mmol/L and 1.5 mmol/L, respectively) for 24 hours and stained for a-tubulin, BubR1, and DAPI. BubR1 staining of kinetochores indicates
an active spindle assembly checkpoint. G, the effects of increasing concentrations of griseofulvin (GF, left) or GF-15 (right), respectively, on tubulin
polymerization were measured by relative Ô¨Çuorescence intensity. All quantitative data shown are the mean  SD of 3 independent experiments.

www.aacrjournals.org

Cancer Res; 72(20) October 15, 2012

5377

Downloaded from 

cancerres.aacrjournals.org 

on July 23, 2015. ¬© 2012 American Association for Cancer Research. 

Published OnlineFirst August 31, 2012; DOI: 10.1158/0008-5472.CAN-12-2026 

Raab et al.

15, the PC-3 prostate carcinoma cell line, which harbors
supernumerary centrosomes in 28  4% of the cells, was
treated with increasing concentrations of the drug for 24
hours (Fig. 1C). Intriguingly, at the highest analyzable con-
centration (1.5 mmol/L), GF-15 induced centrosome declus-
tering‚Äîas deÔ¨Åned by the detection of 2 centrioles at each
spindle pole of multipolar mitoses (Fig. 1D)‚Äîin 27  4% of
the cells, thereby closely matching the total percentage of
cells with supernumerary centrosomes. At the lowest con-
centration tested (0.375 mM), multipolarity induction was
mostly due to inhibition of centrosomal clustering. With
increasing doses of GF-15, the contribution of multipolarity
induction by other means gradually increased. This phe-
nomenon was arbitrarily termed "aberrant," deÔ¨Åned by the
presence of centrioles at only 2 spindle poles despite cells
were undergoing multipolar mitoses. From these results, it
may be concluded that the mechanisms responsible for
holding supernumerary centrosomes together might be sim-
ilar to the forces that bundle microtubules into a bipolar
spindle array in cells with a regular centrosome content.
However, differential sensitivities of both mechanisms may
provide a therapeutic window to preferentially target cen-
trosome clustering at lower dose levels.

Recently, we and others have shown that spindle tension is
required for centrosomal clustering (19, 20). To directly mea-
sure spindle tension, we determined interkinetochore dis-
tances in mitotic PC-3 cells with either bipolar or multipolar
spindles after treatment with 1 mmol/L GF-15 for 24 hours (Fig.
1E). Tension across sister kinetochores was substantially
reduced by GF-15, as indicated by shorter interkinetochore
distances in multipolar metaphase cells. To a lesser but still
signiÔ¨Åcant extent,
interkinetochore distances were also
reduced in metaphase cells that remained bipolar despite
treatment with GF-15. If spindle tension is disturbed, the
spindle assembly checkpoint cannot get sufÔ¨Åciently satisÔ¨Åed
during metaphase and BubR1 should remain at affected kine-
tochores. As shown in Fig. 1F, kinetochores of multipolar
metaphases in GF-15-treated cells stained positive for BubR1
similarly to cells exposed to low-dose taxol, used as a positive
control. In contrast, BubR1 was absent from bipolar meta-
phases in vehicle-treated control cells. Moreover, no MAD2
signal as a marker for disturbed spindle attachment could be
detected at kinetochores of GF-15 induced multipolar meta-
phases, in contrast to kinetochores of cells treated with noco-
dazole as a positive control (data not shown). These Ô¨Åndings
show that GF-15 reduces spindle tension and thereby activates
the spindle assembly checkpoint, but does not disturb micro-
tubule attachment to kinetochores. This corroborates earlier
Ô¨Åndings showing that reduced spindle tension after siRNA-
mediated depletion of kinetochore and spindle components
leads to the formation of multipolar spindles (19, 20).

Effects of griseofulvin and GF-15 on tubulin
polymerization in vitro

To exclude the hypothesis that loss of spindle tension
upon GF-15 exposure is merely a consequence of tubulin
depolymerization, the effects of griseofulvin and GF-15
on the polymerization of puriÔ¨Åed porcine brain tubulin

into microtubules in vitro were analyzed using a Ô¨Çuores-
cence assay (26). Corroborating earlier data, inhibition of
brain tubulin polymerization required very high concentra-
tions of griseofulvin (27, 28). Similarly, the GF-15 concentra-
tions needed for
tubulin polymerization
(25 mmol/L) were about 25-fold above those required for
induction of spindle multipolarity (Fig. 1G).

inhibition of

GF-15 causes multipolar anaphases and cell death in
cells with supernumerary centrosomes

Cells with supernumerary centrosomes only rarely undergo
multipolar divisions. Instead they pass through a transient
multipolar intermediate state followed by centrosome clus-
tering and bipolar anaphase (14, 15). To ascertain that GF-15
indeed induces multipolar cell divisions and subsequent cell
death in cells with supernumerary centrosomes, HeLa cells
were induced to contain extra centrioles by conditional over-
expression of PLK4 (28; Supplementary Fig. S2). In these cells,
in the second cell cycle after centriole overduplication, super-
numerary centrioles disengage before duplication and multi-
polar intermediates are common in the following mitosis
(14, 29). Treatment of HeLa‚ÄìPLK4 cells with increasing con-
centrations of GF-15 for 24 hours, starting 48 hours after
induction of PLK4 expression by addition of doxycycline, led
to a dose-dependent, marked increase in the frequency of
multipolar anaphases with declustered centrosomes (Fig. 2A
and B; Supplementary Fig. S3). In addition, compared with
uninduced cells, GF-15 preferentially decreased the viability
of HeLa cells after PLK4-induced centriole overduplication
(Fig. 2C).

GF-15 is active against a broad spectrum of cancer cell
lines in vitro

leukemia, and myeloma-derived cell

Next, we examined the effect of GF-15 on the growth of
several different cancer cell lines. GF-15 exhibits potent cyto-
toxicity in a concentration-dependent manner against a broad
spectrum of tumor cell types including colon, cervix, glioblas-
toma, pancreas,
lines
(Fig. 3A). As compared with solid tumor cell lines, MM and
leukemia cell lines were particularly susceptible to the cyto-
toxic and antiproliferative effect of GF-15 with IC50 values
ranging from 1 to 2.5 mmol/L. In contrast, GF-15 did not induce
signiÔ¨Åcant cytotoxicity in nonmalignant control cell lines (Fig.
3A) or PBMCs from healthy volunteers even after stimulation
with phytohemagglutinin (PHA), providing an overall selectiv-
ity index of 10- to 30-fold when compared with IC50 values of
cancer cell lines (Fig. 3B). These data suggest that GF-15
exhibits both potent and selective cytotoxicity against malig-
nant cells.

GF-15 is rapidly eliminated in vivo

0

Derived from its parental molecule griseofulvin, GF-15 has
been modiÔ¨Åed at the 2
-position (Fig. 1A). We therefore sought
to analyze the in vivo stability and pharmacokinetics of this
0
new compound. By introducing a p-iodobenzyl group in the 2
-
position of the griseofulvin molecule, we generated a 125I-
labeled GF-15-analogue. HPLC analysis showed only slow
degradation of this molecule in human serum with a half-life

5378

Cancer Res; 72(20) October 15, 2012

Cancer Research

Downloaded from 

cancerres.aacrjournals.org 

on July 23, 2015. ¬© 2012 American Association for Cancer Research. 

Published OnlineFirst August 31, 2012; DOI: 10.1158/0008-5472.CAN-12-2026 

Centrosomal Cluster Inhibition



of 48 hours at 37
C. The cleavage products resulting from
degradation are presumably 4-iodobenzyl alcohol and griseo-
fulvic acid, consistent with the analogue undergoing hydrolysis
(data not shown). After i.v. application of trace amounts of this
analogue, rapid renal clearance was observed within the Ô¨Årst 6
hours after injection (Fig. 3C and D). In light of the clearance
data and the poor solubility of GF-15 at higher concentrations,
we went on to investigate its in vivo efÔ¨Åcacy after intraperi-
toneal application.

GF-15 exhibits in vivo antitumor activity in xenograft
mouse models

In view of the potent and selective in vitro activity of GF-15
against different cancer cell lines, we next examined the in vivo
effect of GF-15 on human tumor growth in immunodeÔ¨Åcient
mice. Two cohorts, each consisting of 30 immunodeÔ¨Åcient
beige-nude-Xid mice were inoculated with either 3 106 OPM2
myeloma or HT29 colon cancer cells s.c. in the right Ô¨Çank.
Treatment with a daily dose of 20 mg/kg (10 mice per cell line)
or 100 mg/kg (10 mice per cell line) intraperitoneally 5 days per
week for 2 weeks was started when tumors became palpable.
Ten mice per cell line served as a control cohort and received
intraperitoneal injections of the vehicle alone. GF-15 treatment
decreased tumor growth in all cohorts of treated mice with a
greater effect in the group that received 100 mg/kg intraper-

itoneally (Figs. 4A, Supplementary Fig. S4). Kaplan‚ÄìMeier and
log-rank analysis revealed a signiÔ¨Åcant prolongation of survival
for the GF-15-treated mice inoculated with OPM2 myeloma
cells compared with the vehicle-treated controls (log-rank P <
0.001; Fig. 4B). For mice inoculated with HT29 colon cancer
cells survival analysis was not feasible because tumors in the
control group rapidly became exulcerated and therefore had to
be sacriÔ¨Åced according to institutional regulations. The tox-
icity proÔ¨Åle of GF-15 seems to be quite favorable as body weight
was not affected by treatment with GF-15 compared with
untreated controls (Fig. 4C). Importantly, examination of
histologic tumor sections revealed a dose-dependent, signiÔ¨Å-
cant increase of aberrant and multipolar mitoses in the GF-15-
treated mice compared with controls (P < 0.01 for 20 mg/kg, P <
0.001 for 100 mg/kg; Fig. 4D and E). In addition, GF-15
signiÔ¨Åcantly increased the mitotic index in treated tumors
versus controls (Supplementary Fig. S5).

Induction of spindle multipolarity, mitotic arrest and
apoptosis by GF-15

As already depicted in Fig. 3A, myeloma cell lines are among
those tumor types with particular susceptibility to GF-15.
Because myeloma cells are known to harbor supernumerary
centrosomes (3‚Äì5), we used MM cells as a model system for
further in-depth analyses. Similar to OPM2, RPMI-8226, NCI-

A

s
e
m
o
s
o
r
t
n
e
c

 

h
t
i

w
 
s
e
s
a
h
p
a
n
a
 
f
o
%

 

 

d
e
i
f
i
l

p
m
a

C

)
l
o
r
t
n
o
c

 
f
o
%

 

(
 

s

l
l

 

e
c
e
l
b
a
i
V

100

80

60

40

20

0

100

80

60

40

20

0

BP clustered       MP declustered

B

Œ±

-Tubulin

Centrin

DAPI                  Merge

O
S
M
D

O
S
M
D

5
1
-
F
G

5
1
-
F
G

0

0.5

0.75

1

1.25 ¬µmol/L

- Dox

+ Dox

0

0.25

0.5

0.75

1

1.25 ¬µmol/L

Figure 2. Centriole ampliÔ¨Åcation sensitizes cells to treatment with GF-15. A, dose-dependent declustering of ampliÔ¨Åed centrosomes and induction of
multipolar (MP) versus clustered bipolar (BP) cell divisions by GF-15 in HeLa cells conditionally expressing PLK4, stained for a-tubulin (red), centrin (green),
and DNA (blue; B). At least 100 anaphases of cells with ampliÔ¨Åed centrioles were counted for each concentration. The Ô¨Årst panel from the top shows a regular
bipolar cell division without centriole ampliÔ¨Åcation compared with the second panel with ampliÔ¨Åed centrioles clustered into bipolar spindle poles.
The third panel displays partial declustering of ampliÔ¨Åed centrioles resulting in tripolar cell division, whereas the fourth panel represents aberrant multipolarity
in a cell without ampliÔ¨Åed centrioles (second centriole at lower pole out of focus). See also Supplementary Fig. S3. Scale bar, 5 mm. C, viable cells were
assessed by MTT cleavage during the last 4 hours of 48-hour cultures of HeLa‚ÄìPLK4 cells with and without doxycycline (Dox, 48 hours) with increasing
concentrations of GF-15. All quantitative data shown are the mean  SD of 3 independent experiments conducted in triplicate.

www.aacrjournals.org

Cancer Res; 72(20) October 15, 2012

5379

Downloaded from 

cancerres.aacrjournals.org 

on July 23, 2015. ¬© 2012 American Association for Cancer Research. 

Published OnlineFirst August 31, 2012; DOI: 10.1158/0008-5472.CAN-12-2026 

Raab et al.

A

Myeloma

Myeloma res.

Leukemia

Solid tumors

Nonmalignant 
controls

C

B

l

)
d
o
f
-
x
(
 

s

l
l

 

l

e
c
e
b
a
V

i

PHA

PBMCs

0

5

10

30

50 ¬µmol/L 

2.5

2

1.5

1

0.5

0

0

0

10

20

30

40

50

60

10

20

30

40

50 ¬µmol/L

5 min

15 min

30 min

1 h

2 h

4 h

6 h

24 h

D

/

g
D

I
 

%

10

8

6

4

2

0

10 min p.i.

30 min p.i.

1 h p.i.

4 h p.i.

8 h p.i.

d
o
o
B

l

t
r
a
e
H

g
n
u
L

n
e
e
p
S

l

r
e
v
L

i

y
e
n
d
K

i

l

e
c
s
u
M

e
n
i
t
s
e
t
n

I

i

n
a
r
B

i

n
k
S

Figure 3. GF-15 selectively inhibits growth of tumor cells in vitro and in vivo . A, IC50 values of cell lines of indicated origins. Unless otherwise indicated, viable
cells were measured by MTT cleavage during the last 4 hours of 48-hour cultures. Data shown are the mean  SD of experiments conducted in triplicate. B,
PBMCs of 3 healthy donors stimulated with PHA do not show signiÔ¨Åcant toxicity upon treatment with indicated concentrations of GF-15. PBMCs were
incubated with PHA 24 hours before exposure to GF-15 for 48 hours. Column colors represent corresponding PBMC samples with or without PHA,
respectively. Viable cells are expressed as x-fold of respective control. C, whole-body scintigraphic images of NMRI mice at indicated times after intravenous
injection of a 125I-labeled GF-15 analogue. D, biodistribution of a 131I-labeled GF-15 analogue at different times after intravenous administration to NMRI mice
(n ¬º 12). Data are expressed as mean %ID/g  SD of each time point. ID, injected dose; p.i., postinjection. All quantitative data shown are the mean  SD of 3
independent experiments.

H929, OPM1, and KMS12BM myeloma cells, myeloma cell lines
resistant to doxorubicin (Dox40), melphalan (LR5), and dexa-
methasone (MM1.R) are susceptible to GF-15 as well (Fig. 5A
and B). Moreover, primary myeloma cells freshly isolated from

the bone marrow of 3 (out of 10) heavily pretreated patients
with relapsed myeloma showed marked cytotoxic effects upon
treatment with GF-15. Lack of efÔ¨Åcacy in the remaining 7
myeloma samples was most likely due to lack of proliferation, a

5380

Cancer Res; 72(20) October 15, 2012

Cancer Research

Downloaded from 

cancerres.aacrjournals.org 

on July 23, 2015. ¬© 2012 American Association for Cancer Research. 

Published OnlineFirst August 31, 2012; DOI: 10.1158/0008-5472.CAN-12-2026 

A

)
3

m
m

l

(
 
e
m
u
o
v
 
r
o
m
u
T

1,400

1,200

1,000
800

600

400

200

0
0

Control

20 mg/kg

100 mg/kg

5

10

15

20 days

C

25

20

15

10

)
g
(
 
t
h
g
e
W

i

5

0

0

Control

E

Control

20 mg/kg

100 mg/kg

Centrosomal Cluster Inhibition

B

)

%

(
 
l

a
v

i

v
r
u
S

100

80

60

40

20

0

D

)

%

(
 

s
n
o
i
t
a
r
r
e
b
a

 

c

i
t
o
t
i

M

80

60

40

20

0

P < 0.001

Control

20 mg/kg

100 mg/kg

0

10

20

30 days

**

*

0

20

100 mg/kg

5

10

15 days

GF-15            
20 mg/kg

GF-15            
100 mg/kg

100x

10x

Figure 4. GF-15 decreases tumor growth, prolongs survival, and induces mitotic aberrations in a MM xenograft mouse model. A, beige-nude Xid mice were
subcutaneously inoculated in the right Ô¨Çank with 3  106 OPM2 cells. Treatment by intraperitoneal injection (vehicle alone or indicated concentrations
of GF-15) was started when tumors were measurable. Arrows indicate treatment stop. Tumor burden was measured every alternating day using an electronic
caliper. Tumor volume is presented as means  SE. B, survival was evaluated using Kaplan‚ÄìMeier curves and log-rank analysis. C, body weight was
evaluated 3 times per week. Data shown are the mean  SD. , P < 0.01; , P < 0.001. D, in hematoxylin and eosin-stained tumor sections (n ¬º 3 per cohort),
at least 200 mitotic cells were analyzed for mitotic aberrations. E, dose-dependent effects of GF-15 on mitotic Ô¨Ågures. ParafÔ¨Ån-embedded sections of
tumor tissue, explanted 24 hours after last treatment, were hematoxylin and eosin-stained and analyzed by light microscopy. Representative microscopic
images are shown.

common phenomenon of primary myeloma cells in tissue
culture. This was in stark contrast to their corresponding
proliferating BMSCs, which displayed virtually no cytotoxicity
when exposed to GF-15 (Fig. 5C). Likewise, after 24 hours of
treatment with 3 mmol/L GF-15, no signiÔ¨Åcant induction of
spindle multipolarity could be detected in mitotic primary
BMSCs, whereas more than 80% of mitoses were multipolar in
NCI H929, OPM2, and RPMI 8226 cells (Fig. 5D). To examine the
effect of multipolar mitosis induction on cell-cycle progression,
starvation-synchronized OPM2 cells were exposed to GF-15,
stained with propidium iodide, and subsequently analyzed by
Ô¨Çow cytometry. GF-15 induced a pronounced G2‚ÄìM cell-cycle
arrest within 12 hours of treatment followed by an increase of
the sub-G1 population compared with mock-treated cells (Fig.
5E, top panel). Indicating the induction of apoptosis, the

increase of the sub-G1 population was concentration-depen-
dent (Fig. 5E, bottom panel), analogous to the effect of gris-
eofulvin in SCC114 cells (13). To further verify apoptotic cell
death triggered by GF-15, protein proÔ¨Åling in GF-15-treated
MM cells showed dose-dependent cleavage of caspase-8,
caspase-9, caspase-3, and PARP (Fig. 5F). Cleavage fragments
of these proteins became detectable at 0.5 mmol/L and strongly
increased at 3 mmol/L of GF-15. Importantly, exposure of
primary BMSCs to 3 mmol/L of GF-15 for 24 hours did not
induce activation of effector caspases-3 and -7 compared with
OPM2 cells (Fig. 5G).

GF-15 inhibits myeloma cell growth triggered by BMSCs
In addition to the effects mediated by growth factors
bone marrow

cytokines within

the myeloma

and

www.aacrjournals.org

Cancer Res; 72(20) October 15, 2012

5381

Downloaded from 

cancerres.aacrjournals.org 

on July 23, 2015. ¬© 2012 American Association for Cancer Research. 

Published OnlineFirst August 31, 2012; DOI: 10.1158/0008-5472.CAN-12-2026 

Raab et al.

OPM2
RPMI 8226 
NCI H929 
OPM1 
KMS12BM
MM1.R
Dox40
LR5

2

4

6

8

10 ¬µmol/L

NCI H929

OPM1

OPM2

X

RPMI 8226

D

E

)

%

(

l

y
t
i
r
a
o
p
i
t
l
u
m
e
d
n
p
S

i

l

 

A

s

l
l

e
c

 

l

e
b
a
V

i

 
 

%

B

n
o
i
t
a
r
e
f
i
l

o
r
P

 
 

%

100

80

60

40

20

0

0

100

80

60

40

20

0

C

F

0

2

4

6

8

10 ¬µmol/L

Control         3 ¬µmol/L GF-15

s
l
l
e
c
 
e
l
b
a
i
V

 
 

%

100

80

60

40

20

0

Primary MM cells

BMSCs

GF-15 (¬µmol/L), 24 h

0        0.5       1       3         5

Blot:
Œ±-Tubulin

Caspase-8
CF
Caspase-9
CF
Caspase-3
CF
PARP
CF

GAPDH

GF-15
24h

G

/

l

)
d
o
f
-
x
(
 
7
3
e
s
a
p
s
a
C

 

100

80

60

40

20

0

Control         3 ¬µmol/L GF-15

BMSCs

MM cell lines

24h

12h

6h

GF-15 (3 ¬µ

0h
mol/L)

Mock

24h

12h

6h

0h

0 ¬µmol/L

3 ¬µmol/L

5 ¬µmol/L

Control        3 ¬µmol/L GF-15

10

8

6

4

2

0

BMSCs

OPM 2

Figure 5. GF-15 speciÔ¨Åcally induces growth inhibition, spindle multipolarity, cell-cycle arrest, and apoptosis in MM cells. A and B, dose-related effects of GF-15
on cell survival (48 hours; A) and proliferation (24 hours; B) on indicated MM cell lines. Cell proliferation was assessed by uptake of [3H]-thymidine during the last
8 hours of 24-hour cultures. C, GF-15 differentially inhibits cell survival of primary cells from MM patients compared with patient BMSCs. D, GF-15 selectively
induces multipolar mitotic spindles in MM cells (NCI H929, OPM2, RPMI 8226; left to right) compared with primary BMSCs from 3 MM patients. At least

5382

Cancer Res; 72(20) October 15, 2012

Cancer Research

Downloaded from 

cancerres.aacrjournals.org 

on July 23, 2015. ¬© 2012 American Association for Cancer Research. 

Published OnlineFirst August 31, 2012; DOI: 10.1158/0008-5472.CAN-12-2026 

microenvironment, direct myeloma‚Äìstroma contact also trig-
gers tumor cell growth and mediates drug resistance. We
therefore evaluated the effect of GF-15 on myeloma cell
proliferation induced by the stimulatory effect of BMSCs (Fig.
6A and B). Binding of OPM2 or RPMI-8226 cells to primary
BMSCs triggered increased myeloma cell proliferation, which
was completely abrogated by GF-15. Importantly, as also
shown in Figs. 5C and D, GF-15 did not impact on BMSCs,
as determined by MTT assays and spindle polarity analysis.

Evaluation of combinations of GF-15 with other
antimyeloma agents

Clinical experience in the therapeutic management of MM
supports the notion that drug combinations can induce higher
response rates when compared with single-agent treatment
(23, 30). We therefore evaluated the effects of combinations of
GF-15 with other established anti-MM drugs on the viability of
MM cells. SpeciÔ¨Åcally, GF-15 was combined with conventional
agents (melphalan) as well as with more recently developed
compounds (bortezomib). Although GF-15 together with bor-
tezomib resulted in additive effects according to isobologram
analysis (e.g., CI ¬º 0.98 for 1.5 mmol/L GF-15 with 1.5 nmol/L
bortezomib), the combination with melphalan led to a marked
abrogation of GF-15 induced cytotoxicity (CI¬º 1.4 for 3 mmol/L
GF-15 with 5 mmol/L melphalan, Fig. 6C). This is consistent
with an S-phase arrest induced by the DNA-damaging drug
melphalan, thereby preventing entry into mitosis of melpha-
lan-exposed cells and underlines the speciÔ¨Åcity of GF-15 for
cells in G2‚ÄìM phase of the cell cycle.
Discussion

We show here that GF-15, a derivative of griseofulvin, leads
to multipolar cell division, loss of spindle tension, centrosomal
declustering, and subsequent tumor-speciÔ¨Åc cell death both in
tissue culture and in xenograft mouse models.

Griseofulvin has been used for many years for the treatment
of dermatophyte infections (31). Mechanistically, it inhibits
mitosis in sensitive fungi (32) and mammalian cells (33, 34) but
whether mitotic arrest is a consequence of microtubule depo-
lymerization or some other action on microtubules in both
fungi and human cells is still unclear (27, 28, 33, 35). Interest-
ingly, in a recent comparison of analogues in fungal and
mammalian cells we found that GF-15 was less active against
dermatophytes than griseofulvin (36). Although griseofulvin
has been reported to bind to mammalian brain tubulin and to
inhibit microtubule polymerization in vitro, it does so only at
concentrations signiÔ¨Åcantly higher than those needed for
spindle multipolarity induction in cancer cells (13, 35). Also,
whether griseofulvin binds to tubulin directly or to microtu-
bule-associated proteins remains unclear (27, 35, 37, 38). It was

Centrosomal Cluster Inhibition

BMSC

OPM2

BMSC/ 
OPM2

0

1

3

5 ¬µmol/L GF-15

BMSC

RPMI 8226

BMSC/ 
RPMI 8226

0

1

3

5 ¬µmol/L GF-15

Control      5 ¬µmol/L

10 ¬µmol/L Mel

A

 

/

4
0
1
x
m
p
c
e
k
a
t
p
u
 
)
T
d
(
H
3

8

6

4

2

0

B

4
0
1
x
 
m
p
c
/
e
k
a
t
p
u
 
)
T
d
(
H
3

20

15

10

5

0

C

)
l
o
r
t
n
o
c
 
f
o
%

 

(
 
s
l
l
e
c
 
e
l
b
a
i
V

100

80

60

40

20

0

0

1.5

3 ¬µmol/L GF-15 

Figure 6. GF-15 abrogates the growth advantage of tumor cells conferred
by adhesion to primary BMSCs. A and B, indicated MM cell lines were
cultured with or without primary BMSCs. GF-15 was added at indicated
concentrations and proliferation was measured by [3H]-thymidine uptake
during the last 8 hours of 24-hour cultures. C, cotreatment of MM cells
with melphalan partially abrogates the growth inhibitory effects of GF-15.
OPM2 cells were treated with indicated concentrations of GF-15 with or
without 5 or 10 mmol/L of melphalan. All quantitative data shown are the
mean  SD of 3 independent experiments conducted in triplicate.

reported more than 30 years ago that griseofulvin treatment
induces spindle multipolarity with each mitotic center con-
taining 2 centrioles in HeLa cells in the absence of signiÔ¨Åcant
spindle microtubule depolymerization (33). In accordance
with these Ô¨Åndings, our data show that griseofulvin signiÔ¨Å-
cantly inhibits polymerization of puriÔ¨Åed tubulin only at the
highest concentration tested (100 mmol/L), although induction

200 mitotic cells were counted for spindle polarity after staining for g-tubulin, Eg5, and 40, 6-diamidino-2-phenylindole. E, synchronized OPM2 cells arrest in
G2‚ÄìM phase upon treatment with GF-15 followed by an increase of the sub-G1 population (top). The increase of the sub-G1 population is dose-dependent
(bottom). OPM2 cells were exposed for indicated times to indicated concentrations of GF-15 and subsequently stained with propidium iodide after ethanol
Ô¨Åxation. F, GF-15 triggers apoptotic cell death in MM cells. OPM2 cells were exposed to indicated concentrations of GF-15 for 24 hours, followed
either by immunoblot analysis of lysates with indicated antibodies or ELISA-based assessment of activation of effector caspases-3 and -7 (G). Identical
treatment of BMSCs showed no signiÔ¨Åcant induction of caspase 3/7 activation compared with OPM2 cells. Results are expressed as x-fold of control. CF,
cleaved form of respective protein. All quantitative data shown are the mean  SD of 3 independent experiments conducted in triplicate.

www.aacrjournals.org

Cancer Res; 72(20) October 15, 2012

5383

Downloaded from 

cancerres.aacrjournals.org 

on July 23, 2015. ¬© 2012 American Association for Cancer Research. 

Published OnlineFirst August 31, 2012; DOI: 10.1158/0008-5472.CAN-12-2026 

Raab et al.

of spindle multipolarity by griseofulvin occurred at an EC50
of 25 mmol/L in SCC114 cells. Similarly, GF-15 inhibits tubulin
polymerization only at concentrations of or above 25 mmol/L,
whereas the EC50 value for multipolar spindle induction was
900 nmol/L in SCC114 cells for this compound. These Ô¨Åndings
suggest that induction of spindle multipolarity by griseofulvin
and its analog GF-15 is not sufÔ¨Åciently explained by their
inhibitory action on tubulin polymerization.

It has recently been shown that cells with supernumerary
centrosomes pass through a transient multipolar spindle
intermediate state before centrosome clustering and subse-
quent bipolar anaphase occur (14, 15). At low concentrations
GF-15 leads to multipolar metaphases with centrioles at each
pole in cells with extra centrioles. At higher concentrations
spindle multipolarity with acentrosomal spindle pole forma-
tion is induced. This is consistent with the concept that
clustering extra centrosomes in cancer cells might be mech-
anistically related to focusing microtubules into a bipolar
spindle array in normal cells. Analysis of GF-15-treated HeLa
cells conditionally overexpressing PLK4 revealed that spindle
multipolarity is carried on into anaphase/telophase with cen-
trioles at each pole in a substantial proportion of cells with
PLK4-induced centriole ampliÔ¨Åcation. Moreover, treatment
with GF-15 increased the death rates of HeLa cells after
induction of PLK4 expression, suggesting that GF-15 prefer-
entially kills cells with ampliÔ¨Åed centrioles.

Recent genome-wide RNAi screens in cells containing super-
numerary centrosomes suggest that only an intact spindle
assembly checkpoint allows for sufÔ¨Åcient time for centrosomal
clustering to occur and that spindle tension is necessary for
clustering of supernumerary centrosomes into a bipolar mitot-
ic spindle array (19, 20). Determination of spindle tension in
mitotic cells revealed that tension across sister kinetochores
was substantially reduced by GF-15 in both multipolar meta-
phase cells and metaphase cells that remained bipolar despite
treatment with GF-15. In addition to microtubule depolymer-
ization or stabilization at higher concentrations, most micro-
tubule-interacting drugs,
including griseofulvin, have been
proposed to exert their effects by suppressing microtubule
dynamics (35, 38). Interestingly, interference with microtubule
dynamics has been described to cause loss of spindle tension
across kinetochores (39, 40). Therefore, it is conceivable that
GF-15 inhibits microtubule dynamic instability with subse-
quent loss of spindle tension, centrosome declustering in cells
with supernumerary centrosomes, multipolar cell division, and
ultimately cell death.

For GF-15, the EC50 value for multipolar spindle induction in
vitro was 900 nmol/L in SCC114 cells, corresponding to a 27-
fold increased activity compared with griseofulvin itself. Also,
whereas griseofulvin inhibits cell proliferation only weakly
with half-maximal inhibition occurring at 25 mmol/L (13),
GF-15 led to inhibition of tumor cell growth in vitro at IC50
values of 1 to 3 mmol/L, with almost no impact on the
viability of nonmalignant control cell lines. Similarly, although
3 mmol/L GF-15 effectively decreased the viability of primary
patient myeloma cells, the drug induced neither spindle mul-
tipolarity nor cell death in primary BMSCs or primary PBMCs
even after mitogenic stimulation. In vivo, GF-15 was well

tolerated and effective in mouse myeloma and colon cancer
xenograft models, as evidenced by signiÔ¨Åcant inhibition of
tumor growth, the induction of spindle multipolarity in tumor
xenograft cells and prolonged survival in mice treated with
either 20 or 100 mg/kg GF-15 intraperitoneally daily for 5 days a
week. Because GF-15 is only poorly soluble in water and its
biologic half-life is short with little drug left 1 hour after
administration, it is expected that optimization of medicinal
chemistry and application schedules will lead to a further
improvement of the drugs potency and of this novel thera-
peutic strategy in general.

In summary, we have shown that GF-15 potently inhibits
tumor cell growth in vitro and in vivo. From a mechanistic point
of view our data reveal that GF-15 reduces spindle tension,
possibly via inhibition of microtubule dynamic instability,
leading to spindle multipolarity in cells with supernumerary
centrosomes, similar to what has been described for the siRNA-
mediated depletion of several spindle and kinetochore com-
ponents (19, 20). These observations, coupled with GF-15's lack
of major toxicity in a preclinical mouse model and the lack of
signiÔ¨Åcant toxicity of griseofulvin in humans, provide the
framework for further clinical development of GF-15 in par-
ticular and centrosomal cluster inhibitors in general, directed
at improving patient outcome.

Disclosure of Potential ConÔ¨Çicts of Interest

K.C. Anderson is an ACS Clinical Research Professor. No potential conÔ¨Çicts of

interest were disclosed by the other authors.

Authors' Contributions
Conception and design: M.S. Raab, I. Breitkreutz, W. Mier, M.H. Clausen,
A. Kr‚Ç¨amer
Development of methodology: I. Breitkreutz, M.H. Ronnest, W. Mier, A.
Kr‚Ç¨amer
Acquisition of data (provided animals, acquired and managed patients,
provided facilities, etc.): M.S. Raab, I. Breitkreutz, M.H. Ronnest, B. Leber,
L. Weiz, G. Konotop, K. Podar, J. Fruehauf, F. Nissen, W. Mier, U. Haberkorn
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): M.S. Raab, I. Breitkreutz, M.H. Ronnest, B. Leber,
F. Nissen, M.H. Clausen, A. Kr‚Ç¨amer
Writing, review, and/or revision of the manuscript: M.S. Raab, I. Breitk-
reutz, M.H. Ronnest, T.O. Larsen, P.J. Hayden, K. Podar, J. Fruehauf, W. Mier,
H. Goldschmidt, K.C. Anderson, M.H. Clausen, A. Kr‚Ç¨amer
Administrative, technical, or material support (i.e., reporting or orga-
nizing data, constructing databases): I. Breitkreutz, A.D. Ho
Study supervision: A. Kr‚Ç¨amer
Performing experiments: S. Anderhub

Acknowledgments

The authors thank Ingrid Hoffmann, PhD, German Cancer Research Center,
for providing the conditional HeLa-PLK4 cell line and J. Salisbury (Rochester) for
the centrin antibody. The authors also thank Anja Baumann for excellent
technical assistance.

Grant Support

This work was supported by a grant of the Max-Eder-Program, Deutsche
Krebshilfe (M.S. Raab); the Hopp-Foundation (H. Goldschmidt); the DFG (A.
Kr‚Ç¨amer); a Deutsche Krebshilfe grant (M.S. Raab and A. Kr‚Ç¨amer); the Tumor-
zentrum Heidelberg/Mannheim (A. Kr‚Ç¨amer); the Danish Research Council (ref.
274-07-0561; M.H. Ronnest, T.O. Larsen, and M.H. Clausen); the Danish Cancer
Society and Karen Krieger Fonden (M.H. Clausen); the NIH grants RO CA50947,
PO-1 CA78378, and P50 CA100707 (K.C. Anderson).

The costs of publication of this article were defrayed in part by the payment of
page charges. This article must therefore be hereby marked advertisement in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 29, 2012; revised August 6, 2012; accepted August 21, 2012;

published OnlineFirst August 31, 2012.

5384

Cancer Res; 72(20) October 15, 2012

Cancer Research

Downloaded from 

cancerres.aacrjournals.org 

on July 23, 2015. ¬© 2012 American Association for Cancer Research. 

Published OnlineFirst August 31, 2012; DOI: 10.1158/0008-5472.CAN-12-2026 

References
1. Doxsey S. Re-evaluating centrosome function. Nat Rev Mol Cell Biol

2001;2:688‚Äì98.

2. Kr‚Ç¨amer A, Neben K, Ho AD. Centrosome replication, genomic insta-

bility and cancer. Leukemia 2002;16:767‚Äì75.

3. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR,
Gertz MA, et al. Clinical implication of centrosome ampliÔ¨Åcation in
plasma cell neoplasm. Blood 2006;107:3669‚Äì75.

4. Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R, et al.
The centrosome index is a powerful prognostic marker in myeloma and
identiÔ¨Åes a cohort of patients that might beneÔ¨Åt from aurora kinase
inhibition. Blood 2008;111:1603‚Äì9.

5. Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Reiman T. Receptor for
hyaluronan-mediated motility correlates with centrosome abnormal-
ities in multiple myeloma and maintains mitotic integrity. Cancer Res
2005;65:850‚Äì60.
Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL. Centrosome
hypertrophy in human breast tumors: implications for genomic stability
and cell polarity. Proc Natl Acad Sci U S A 1998;95:2950‚Äì5.

6.

7. Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P,
et al. Centrosome defects and genetic instability in malignant tumors.
Cancer Res 1998;58:3974‚Äì85.

8. Nigg EA. Centrosome aberrations: cause or consequence of cancer

progression? Nat Rev Cancer 2002;2:815‚Äì25.

9. Neben K, Giesecke C, Schweizer S, Ho AD, Kr‚Ç¨amer A. Centrosome
aberrations in acute myeloid leukemia are correlated with cytogenetic
risk proÔ¨Åle. Blood 2003;101:289‚Äì91.

10. Kr‚Ç¨amer A, Schweizer S, Neben K, Giesecke C, Kalla J, Katzenberger T,
et al. Centrosome aberrations as a possible mechanism for chromo-
somal
instability in non-Hodgkin's lymphoma. Leukemia 2003;17:
2207‚Äì13.

11. Levine DS, Sanchez CA, Rabinovitch PS, Reid BJ. Formation of the
tetraploid intermediate is associated with the development of cells with
more than four centrioles in the elastase-simian virus 40 tumor antigen
transgenic mouse model of pancreatic cancer. Proc Natl Acad Sci
U S A 1991;88:6427‚Äì31.

12. Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ.
Centrosome defects can account for cellular and genetic changes
that characterize prostate cancer progression. Cancer Res 2001;61:
2212‚Äì9.

13. Rebacz B, Larsen TO, Clausen MH, R√∏nnest MH, L‚Ç¨ofÔ¨Çer H, Ho AD,
et al.
IdentiÔ¨Åcation of griseofulvin as an inhibitor of centrosomal
clustering in a phenotype-based screen. Cancer Res 2007;67:
6342‚Äì50.

14. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra

centrosomes to chromosomal instability. Nature 2009;460:278‚Äì82.

15. Silkworth WT, Nardi IK, Scholl LM, Cimini D. Multipolar spindle pole
coalescence is a major source of kinetochore mis-attachment and
chromosome mis-segregation in cancer cells. PLoS One 2009;
4:e6564.

16. Ring D, Hubble R, Kirschner M. Mitosis in a cell with multiple centrioles.

J Cell Biol 1982;94:549‚Äì56.

17. Brinkley BR. Managing the centrosome numbers game: from chaos to

stability in cancer cell division. Trends Cell Biol 2001;11:18‚Äì21.

18. Quintyne NJ, Reing JE, Hoffelder DR, Gollin SM, Saunders WS. Spindle
multipolarity is prevented by centrosomal clustering. Science 2005;
307:127‚Äì9.

19. Kwon M, Godinho SA, Chandhok NS, Ganem NJ, Azioune A, Thery M,
et al. Mechanisms to suppress multipolar divisions in cancer cells with
extra centrosomes. Genes Dev 2008;22:2189‚Äì203.

20. Leber B, Maier B, Fuchs F, Chi J, Riffel P, Anderhub S, et al. Proteins
required for centrosome clustering in cancer cells. Sci Transl Med
2010;2:33ra38.

Centrosomal Cluster Inhibition

21. R√∏nnest MH, Rebacz B, Markworth L, Terp AH, Larsen TO, Kr‚Ç¨amer A,
et al. Synthesis and structure-activity relationship of griseofulvin ana-
logues as inhibitors of centrosomal clustering in cancer cells. J Med
Chem 2009;52:3342‚Äì7.

22. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, et al.
Vascular endothelial growth factor triggers signaling cascades medi-
ating multiple myeloma cell growth and migration. Blood 2001;98:
428‚Äì35.

23. Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Mitsiades C,
et al. Antitumor activity of lysophosphatidic acid acyltransferase-beta
inhibitors, a novel class of agents, in multiple myeloma. Cancer Res
2003;63:8428‚Äì36.


24. Kr‚Ç¨amer A, Mailand N, Lukas C, Syljua

sen RG, Wilkinson CJ, Nigg EA,
et al. Centrosome-associated Chk1 prevents premature activation of
cyclin-B-Cdk1 kinase. Nat Cell Biol 2004;6:884‚Äì91.

25. Gomez C, Huerta FF, Yus M. DTBB-catalysed lithiation of chlorinated
benzylic chlorides, alcohols, thiols or amines. Tetrahedron 1998;54:
1853‚Äì66.

26. Shelanski ML, Gaskin F, Cantor CR. Microtubule assembly in the
absence of added nucleotides. Proc Natl Acad Sci U S A 1973;70:
765‚Äì8.

27. Weber K, Wehland J, Herzog W. Griseofulvin interacts with micro-

tubules both in vivo and in vitro. J Mol Biol 1976;102:817‚Äì29.

28. Wehland J, Herzog W, Weber K.

Interaction of griseofulvin with
microtubules, microtubule protein and tubulin. J Mol Biol 1977;111:
329‚Äì42.

29. Cizmecioglu O, Arnold M, Bahtz R, Settele F, Ehret L, Haselmann-
Weiss U , et al. Cep152 acts as a scaffold for recruitment of Plk4 and
CPAP to the centrosome. J Cell Biol 2010;191:731‚Äì9.

30. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC.

Multiple myeloma. Lancet 2009;374:324‚Äì39.

31. Loo DS. Systemic antifungal agents: an update of established and new

therapies. Adv Dermatol 2006;22:101‚Äì24.

32. Gull K, Trinci APJ. Griseofulvin inhibits fungal mitosis. Nature

1973;244:292‚Äì4.

33. Grisham LM, Wilson L, Bensch KG. Antimitotic action of griseofulvin
does not involve disruption of microtubules. Nature 1973;244:294‚Äì6.
34. Ho YS, Duh JS, Jeng JH, Wang YJ, Liang YC, Lin CH, et al. Griseofulvin
potentiates antitumorigenesis effects of nocodazole through induction
of apoptosis and G2/M cell cycle arrest in human colorectal cancer
cells. Int J Cancer 2001;91:393‚Äì401.

35. Panda D, Rathinasamy K, Santra MK, Wilson L. Kinetic suppression of
microtubule dynamic instability by griseofulvin: implications for its
possible use in the treatment of cancer. Proc Natl Acad Sci U S A
2005;102:9878‚Äì83.

36. R√∏nnest MH, Raab MS, Anderhub S, Boesen S, Kr‚Ç¨amer A, Larsen TO,
et al. Disparate SAR data of griseofulvin analogues for the dermato-
phytes Trichophyton mentagrophytes, T. rubrum, and MDA-MB-231
cancer cells. J Med Chem 2012;55:652‚Äì60.

37. Roobol A, Gull K, Pogson CI. Evidence that griseofulvin binds to a

microtubule associated protein. FEBS Lett 1977;75:149‚Äì53.

38. Rathinasamy K, Jindal B, Asthana J, Singh P, Balaji PV, Panda D.
Griseofulvin stabilizes microtubule dynamics, activates p53 and inhi-
bits the proliferation of MCF-7 cells synergistically with vinblastine.
BMC Cancer 2010;10:213.

39. Zhou J, Panda D, Landen JW, Wilson L, Joshi HC. Minor alteration
of microtubule dynamics causes loss of tension across kinetochore
pairs and activates the spindle checkpoint. J Biol Chem 2002;
277:17200‚Äì8.

40. Rathinasamy K, Panda D. Suppression of microtubule dynamics by
benomy decreases tension across kinetochore pairs and induces
apoptosis in cancer cells. FEBS J 2006;273:4114‚Äì28.

www.aacrjournals.org

Cancer Res; 72(20) October 15, 2012

5385

Downloaded from 

cancerres.aacrjournals.org 

on July 23, 2015. ¬© 2012 American Association for Cancer Research. 

Published OnlineFirst August 31, 2012; DOI: 10.1158/0008-5472.CAN-12-2026 

GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses
Tumor Cell Growth 
In Vitro
¬† 
Marc S. Raab, Iris Breitkreutz, Simon Anderhub, et al. 
¬† 
Cancer Res¬†

2012;72:5374-5385. Published OnlineFirst August 31, 2012.

 and 

In Vivo
 

¬† 
¬† 
¬† 
¬† 

¬† 
¬† 

Updated version
¬† 
Supplementary
Material
¬† 

10.1158/0008-5472.CAN-12-2026
 

Access the most recent version of this article at:
doi:
¬† 
Access the most recent supplemental material at:
 
http://cancerres.aacrjournals.org/content/suppl/2012/08/31/0008-5472.CAN-12-2026.DC1.html
¬† 

Cited articles
¬† 
Citing articles
¬† 

This article cites 40 articles, 19 of which you can access for free at:
http://cancerres.aacrjournals.org/content/72/20/5374.full.html#ref-list-1
 
¬† 
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/72/20/5374.full.html#related-urls
 
¬† 

E-mail alerts
¬† 
Reprints and 
Subscriptions
¬† 
Permissions
¬† 

Sign up to receive free email-alerts

 related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
pubs@aacr.org
.
¬† 
To request permission to re-use all or part of this article, contact the AACR Publications Department at
.
permissions@aacr.org
¬† 

Downloaded from 

cancerres.aacrjournals.org 

on July 23, 2015. ¬© 2012 American Association for Cancer Research. 

